Warwick Davis' wife's cause of death revealed as arrhythmic cardiac arrest
Warwick Davis' wife's cause of death has been revealed as arrhythmic cardiac arrest. Samantha Davis died aged 53 on 24 March, 2024, and an inquest on Monday (14.04.25) at Inner West London Coroner's Court heard the actress – who had the achondroplasia form of dwarfism – underwent a thoracic discectomy at the National Hospital for Neurology and Neurosurgery in London on 20 February 2024 and passed away following complications linked to her spinal surgery. The procedure, intended to address semi-paralysis in her legs, involved cutting through her ribs and deflating a lung. Post-surgery, she suffered a haemothorax, leading to the drainage of approximately one litre of fluid. She was then transferred to University College London Hospital for observation. After a second haemothorax in March, Samantha showed signs of improvement and was scheduled for discharge on 24 March. However, she went into cardiac arrest shortly before midnight on 23 March and was pronounced dead in the early hours of the following day. Resuscitation efforts lasted 53 minutes. Pathologist Dr John Firth attributed her death to a left haemothorax resulting from surgical complications, noting the presence of over 700ml of blood and clots. However, some medical professionals offered differing opinions. Cardiothoracic surgeon Mr David Lawrence stated a chest x-ray taken the day before her death appeared satisfactory and suggested that the bleeding was more likely caused by CPR. Consultant spinal surgeon Mr Adrian Casey, who performed the discectomy, remarked such blood loss was 'unlikely to cause death' and described the cause as 'somewhat unexplained'. Dr Katherine Hunt, UCLH's clinical lead for resuscitation, said Samantha's bleed was more likely a result of CPR and identified signs of an abnormal heart rhythm on the defibrillator rhythm strip. Senior Coroner Professor Fiona Wilcox concluded the actress passed away from arrhythmic cardiac arrest following complications from spinal surgical treatment. She stated: 'On the balance of probabilities, the stress of her surgeries and the complications that arose precipitated the arrhythmia.' Professor Wilcox emphasised Samantha received 'nothing but excellent care' and added: 'All of her complications were appropriately managed. It's heartbreaking that the surgery was successful only for complications to arise and cause her death."' Warwick, 55, and his family, represented by medical negligence lawyers, attended the inquest seeking clarity on the circumstances surrounding Samantha's death. In a statement released through their solicitors, the family expressed hope the inquest would provide them with answers and thanked everyone for their kindness and well-wishes. Samantha, who co-founded the charity Little People UK in 2012, met Warwick in 1988 on the set of the film 'Willow'. They married in 1991 and had two children, Annabelle, 27, and 21-year-old Harrison. The couple experienced the loss of two sons – Lloyd, who died at nine days old in 1991, and George, who was lost during pregnancy.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
04-06-2025
- Yahoo
Jury hits Presbyterian with $40 million verdict in medical negligence case
Jun. 4—A jury this week awarded more than $40 million in damages to a couple who argued that personnel at Presbyterian Healthcare Services failed to diagnose a condition that resulted in brain damage to their infant child. The couple argued in a lawsuit that Presbyterian personnel failed to diagnose the infant's low blood glucose levels after the child's birth in April 2019, resulting in permanent developmental effects. The award included $15 million in punitive damages against Presbyterian. Jurors also awarded nearly $25 million to the child, now 6, and a total of $825,000 to the boy's parents, Samantha and Patrick Leonard. Jurors also found that the conduct of four Presbyterian personnel, including two physicians and two registered nurses, showed "reckless or wanton" behavior on the part of the health care system, 2nd Judicial District Court records show. Jurors handed down the verdict on Monday following a two-week trial before state District Judge Denise Barela-Shepherd. Presbyterian called the judgment "excessive" in a statement issued Tuesday. "While we respect the judicial process, we have serious concerns about this outcome and the unprecedented size of the damages awarded," the statement said. "We intend to pursue legal options to address what we consider to be an excessive judgment." "Presbyterian is committed to providing safe, high-quality care to our communities," it said. The verdict comes about six months after a Bernalillo County jury awarded nearly $17 million in damages to a woman who carried a 13-inch metal instrument in her abdomen for two months following a 2019 surgery at Presbyterian Hospital. That Jan. 14 verdict included $15 million in punitive damages against Presbyterian. Earlier this year, lawmakers failed to approve a bill that sought to counter the shortage of health care providers in New Mexico by changing the state's Medical Malpractice Act, including limiting attorney fees in medical malpractice cases. Senate Bill 176 died in committee after drawing strong opposition from trial lawyers and patients injured by medical malpractice. Supporters of the bill argued that New Mexico's medical malpractice laws have made the state a magnet for out-of-state attorneys and discouraged doctors from practicing here. In 2022, New Mexico had the highest medical malpractice insurance loss ratio in the country, according to a recent Think New Mexico report, meaning insurers paid out 183% of the premiums they took in. Indeed, New Mexico was one of only seven states where insurers lost money, making it much more expensive for them to function in this market. Lisa Curtis, an Albuquerque attorney who represented the Leonard family, said jurors awarded $15 million in punitive damages as a warning to Presbyterian. "It's clear they were just trying to send a message — take better care of our children," Curtis said Tuesday. An attorney for Presbyterian Healthcare Services, Colleen Koch, did not immediately return phone messages Tuesday seeking comment. The boy, who was born about three weeks prematurely at Presbyterian Hospital in April 2019, had undetected hypoglycemia, or low blood sugar, due to high insulin levels, according to the 2022 lawsuit. The boy was discharged from the hospital two days after birth. Seven days after discharge, the boy became "fussy and febrile with less active feeding" and was readmitted to Presbyterian. Eight days after the boy's birth, his brain and heart shut down, Curtis said. "They started testing his blood sugar after that," she said. "His blood sugars were super low. They figured it out in a day once he had crashed and they tested him." Presbyterian violated its own policies that require blood-sugar testing for all babies born prematurely within 24 hours of birth, Curtis argued. The boy "suffered undetected hypoglycemia with subsequent seizure activity and respiratory arrest when he was only (8) days old," the lawsuit said. The boy "is suffering the long-term consequences of developmental delay/sensory disorder, abnormal vision and behavioral effects."
Medscape
03-06-2025
- Medscape
Enpatoran Shows Promise in Treating Lupus Rash
An oral therapy targeting toll-like receptors (TLR) 7 and 8 reduced disease activity in patients with cutaneous lupus erythematosus (CLE) or systemic lupus erythematosus (SLE) with active lupus rash. METHODOLOGY: Cohort A of the phase 2 WILLOW study included patients with CLE and patients with mild SLE and active skin manifestation for whom no approved treatments currently exist. In the study of the oral, small molecule TLR 7/8 inhibitor enpatoran, researchers randomly assigned 100 patients, all receiving standard-of-care medications, to placebo, 25 mg enpatoran, 50 mg enpatoran, or 100 mg enpatoran twice daily for 24 weeks. The primary endpoint was percent change in CL Disease Area and Severity Index Activity (CLASI-A) from baseline to week 16. TAKEAWAY: Patients taking enpatoran all had clinically meaningful reductions to CLASI-A at week 16, with reductions of 74.6% for the group taking 25 mg twice daily, 59.8% for 50 mg twice daily, 68.5% for 100 mg twice daily, and 41.2% for placebo. A total of 87% of patients taking 25 mg twice daily achieved ≥ 50% reduction in CLASI-A by week 24 compared with 72% for 50 mg twice daily, 73.1% for 100 mg twice daily, and 30.8% for placebo. All patients on enpatoran also had reduced interferon gene signatures by week 2 compared with placebo, and this effect was continued through week 24. Enpatoran was well-tolerated with no new safety signals from previous clinical studies. Treatment-emergent adverse events occurred in 46% with placebo, and at rates of 57.7%-80.8% in enpatoran treatment groups. IN PRACTICE: 'The new findings from WILLOW provide promising evidence that enpatoran could enhance treatment options for these patients, addressing the suboptimal care typically available for those with CLE- and SLE-related skin manifestations,' said a spokesperson for EMD Serono, the healthcare business of Merck KGaA in the United States. SOURCE: Eric Morand, MD, of Monash University, Melbourne, Australia, presented the study at the 16th International Congress on Systemic Lupus Erythematosus in Toronto, Ontario, Canada. LIMITATIONS: The relatively small sample size of the trial and short duration could limit the ability to detect clinically meaningful differences in efficacy and longer-term outcomes. DISCLOSURES: Merck KGaA, based in Darmstadt, Germany, funded the research. Presenter and principal investigator Eric Morand, MD, of Monash University in Melbourne, Australia, reported financial relationships with 17 pharmaceutical companies, several of which manufacture lupus drugs.
Yahoo
02-06-2025
- Yahoo
Man fights against deadly disease that killed dog after walk near Swindon
A man is continuing his fight against the deadly disease that killed his dog after a walk near Swindon. Shaun Reynolds lost his dog, Willow, to Alabama Rot, a rare disease that affects dogs, last year. Since then, he has been raising money for the Alabama Rot Research Fund. He has already raised £15,000, and hopes to reach his £20,000 target this month. Read more: Record-breaking beer and cider festival attracts over 1,400 people To help him reach his goal, he has organised a fundraising event called 'A Celebration of Willow #2' at Lambourn Sports Club on Sunday, June 29. The event will feature seven live whippet races on a purpose-built track on the club's football pitch. There will also be a three-piece traditional Irish band to entertain the crowds. Other activities include life-sized garden games, a bouncy castle, a charity Tote, a silent auction, and the chance for people to run their own dogs behind the lure ahead of the races. Food and drink will be provided by local vendors. Mr Reynolds hopes to raise £5,000 at the event. He said: "Last year blew me away. "I thought the event would be popular, but the turnout went beyond what I expected and everyone was complimentary afterwards which meant the world. "Willow's story has touched millions of people. "While losing her was completely devastating and still upsets me each day, her legacy can be to ensure as few dogs as possible go through what she experienced at the end." Willow died after 21 days of intensive care treatment. There is no cure for Alabama Rot, and it is not known how it is caught. An estimated 90 per cent of dogs infected die. To date, 338 cases of Alabama Rot have been confirmed. Mr Reynolds added: "There have been no reported cases of Alabama Rot within 40 miles of Lambourn – where she was infected – in the last year. "That hasn't happened since the disease was first identified over a decade ago. "It's impossible to know for sure, but I'd like to think she's helped to save a life or two. Read more: Swindon and Wiltshire Pride appoints first-ever patron "I'd love to see as many people trackside on June 29 for a genuinely fantastic and fun day out for all the family all for a fiver, with all proceeds going to the Alabama Rot Research Fund. "Hopefully see you then." Admission for 'A Celebration of Willow #2' is priced at £5, with the option for racegoers to pay £10, £15, or £20 per ticket should they wish to contribute additional funds. Cash is accepted on the day. Doors open at 1pm, with the first of seven races starting at 3pm. Parking is available onsite.
